Phenotypes Associated with This Genotype

Genotype
MGI:3639676

• Allelic Composition: Dnase1^tm1Tmo/Dnase1^tm1Tmo
• Genetic Background: involves: 129P2/OlaHsd * CD-1

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

decreased susceptibility to xenobiotic induced morbidity/mortality ( J:110060 )

• after injection of cisplatin, mortality of null mice at days 3-4 is significantly reduced compared to wild-type

homeostasis/metabolism

decreased circulating creatinine level ( J:110060 )

• knockouts have decreased creatinine levels (0.9 mg/dl) compared to wild-type (2.7 mg/dl)

decreased blood urea nitrogen level ( J:110060 )

• knockouts have decreased BUN levels (125 mg/dl) compared to wild-type (250 mg/dl)

decreased susceptibility to xenobiotic induced morbidity/mortality ( J:110060 )

• after injection of cisplatin, mortality of null mice at days 3-4 is significantly reduced compared to wild-type

immune system

decreased susceptibility to systemic lupus erythematosus ( J:110060 )

• Background Sensitivity: on a CD-1 background mice do not develop lupus but Dnase1-deficient mice on a 129 x C57BL/6 background do

renal/urinary system

decreased kidney apoptosis ( J:110060 )

• in null mice, no apoptotic bodies are observed while some are found in wild-type mice

• DNA fragmentation is significantly decreased in null mice after cisplatin treatment compared to wild-type mouse tissue

renal tubular necrosis ( J:110060 )

• necrosis is significantly decreased in Dnase1-null mice compared to wild-type after cisplatin treatment

kidney failure ( J:110060 )

• at day 4, wild-type mice show marked kidney failure, whereas knockouts are significantly protected

cellular

decreased kidney apoptosis ( J:110060 )

• in null mice, no apoptotic bodies are observed while some are found in wild-type mice

• DNA fragmentation is significantly decreased in null mice after cisplatin treatment compared to wild-type mouse tissue